Role of disease risk scores in comparative effectiveness research with emerging therapies - Wikidata - awgldk - TriplyDB

Role of disease risk scores in comparative effectiveness research with emerging therapies

Role of disease risk scores in comparative effectiveness research with emerging therapies

http://www.wikidata.org/entity/Q36266471

about

Disease risk score as a confounder summary method: systematic review and recommendations A modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment.Dimension reduction and shrinkage methods for high dimensional disease risk scores in historical data.Risk of incident active tuberculosis disease in patients treated with non-steroidal anti-inflammatory drugs: a population-based study Reducing Bias Amplification in the Presence of Unmeasured Confounding Through Out-of-Sample Estimation Strategies for the Disease Risk Score.A counterfactual approach to bias and effect modification in terms of response types.Model Misspecification When Excluding Instrumental Variables From PS Models in Settings Where Instruments Modify the Effects of Covariates on Treatment Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.Refining the definition of clinically important mineral and bone disorder in hemodialysis patients On the use of propensity scores in case of rare exposure.External validation and comparison of two variants of the Elixhauser comorbidity measures for all-cause mortality Matching on the disease risk score in comparative effectiveness research of new treatments Comparison of Calipers for Matching on the Disease Risk Score Angiotensin-Converting Enzyme Inhibitors and Active Tuberculosis: A Population-Based Study.Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research.Evaluation of propensity scores, disease risk scores, and regression in confounder adjustment for the safety of emerging treatment with group sequential monitoring.New methods for determining comparative effectiveness in rheumatoid arthritis CKD-mineral and bone disorder and risk of death and cardiovascular hospitalization in patients on hemodialysis.Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study On the joint use of propensity and prognostic scores in estimation of the average treatment effect on the treated: a simulation study.Statin treatment is associated with a decreased risk of active tuberculosis: an analysis of a nationally representative cohort.Control of confounding in the analysis phase - an overview for clinicians.The "Dry-Run" Analysis: A Method for Evaluating Risk Scores for Confounding Control.Performance of the disease risk score in a cohort study with policy-induced selection bias.Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.Regularized Regression Versus the High-Dimensional Propensity Score for Confounding Adjustment in Secondary Database Analyses.Performance of Disease Risk Score Matching in Nested Case-Control Studies: A Simulation Study.On the use and misuse of scalar scores of confounders in design and analysis of observational studies.Severe hepatic injury associated with different statins in patients with chronic liver disease: a nationwide population-based cohort study.Empirical performance of a new user cohort method: lessons for developing a risk identification and analysis system.Study protocol for the dabigatran, apixaban, rivaroxaban, edoxaban, warfarin comparative effectiveness research study.Association of Higher Daptomycin Dose (7 mg/kg or Greater) with Improved Survival in Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia.Development and application of two semi-automated tools for targeted medical product surveillance in a distributed data network.Methods for addressing "innocent bystanders" when evaluating safety of concomitant vaccines.New-user designs with conditional propensity scores: a unified complement to the traditional active comparator new-user approach.Estimation of conditional and marginal odds ratios using the prognostic score.Comparison of privacy-protecting analytic and data-sharing methods: A simulation study Opportunities and Challenges in Using Epidemiologic Methods to Monitor Drug Safety in the Era of Large Automated Health Databases

P2860

Q26999267-E466E11E-C8DA-4FAD-9F1F-75DCCD812DEB Q30812957-82267561-5ECB-4168-B298-7C924DE0E752 Q31070556-B45AF416-C5C9-4C09-ABAB-1AC4A6D30068 Q33640404-C04CD821-1219-4D2F-9F83-51F073AA3C66 Q34323908-5C695B9C-8455-420C-9F36-6CC78F205EDE Q34884247-F6A9956A-A29E-4C77-A084-14F4AB942D20 Q35056126-631E1DE9-8B75-43BD-BFC7-CD3E0B69D0AC Q35636624-54E343EE-B8A9-4AFE-B21E-3F453A0B1E27 Q35886018-9C6367D5-33F4-4352-B270-FD53B03D607A Q35977320-421A71C7-0052-4362-A65D-EDB57B9FEB7B Q36325329-8D18963B-00A7-410D-9ADF-3B5ACA83F2B1 Q36802843-DA42CB65-29CB-4EB3-BFCC-E140C8BA0E4B Q36901648-7951B130-FEB4-4DFD-8437-41D9B2373901 Q36993403-5E2C4B60-30C9-4CE5-8CD3-5FAC709BFBC3 Q37019503-528FB1E7-A6A7-4E9D-B3EF-0209983620FC Q37059085-A3BCBACD-7366-4A5A-A4C8-241F557B36B4 Q37274242-D0069941-54F9-4E25-819A-901FC7A363F8 Q37359078-A2CB88BB-FA7E-466A-A272-F98CCEC90BB2 Q37527438-56CEA304-0FF1-4654-84B5-5EC88A8841D6 Q37716995-EAFDC63E-88F7-4C2E-ADC9-3CE1D07501A6 Q38409346-915629BC-1AEB-4148-8B0C-D0497B4CD162 Q38837483-87F395AB-9C05-4F6E-AC6D-A6549A9282CF Q40275826-10D45CED-48A8-462D-AF60-0D55312172AC Q40361680-AB994EFE-21A7-4666-ADFE-292B7A47CA66 Q40598586-A71C8C79-810E-4726-A1BB-A9348505A706 Q40669508-052A1B67-9321-4109-B2B7-2A3D26AC078D Q40749744-D4EC1242-98A7-4125-895B-40E78C38D24E Q41203763-51C4B53C-CF2E-47A3-8861-23BBCAC4CEF1 Q44324185-4097B850-FA46-4989-A308-A98F2A16EB97 Q45908499-EF57B64F-594C-4814-8501-BCC3CA1ACC51 Q47271377-930909FE-0E2C-4E0E-A9C9-CF04628E866E Q47318913-9FC5EC9B-E954-428A-8450-899F5EA8DBC3 Q47369849-C0EF66C6-97B6-48DF-B74E-FC21CDF7EDBD Q50020169-8D07AFCE-63A2-46BF-ABCF-4ECB824E4457 Q53490427-FC7818BD-AF8A-4A56-8863-2BF3134E599E Q53675598-54B4225B-0726-45F5-BC81-27B8F026C390 Q56395435-75066F13-97CE-46A8-906E-D31021FA9D01 Q57608720-138963FD-6B36-4AD5-8B47-3A49926BD7FE

P2860

Role of disease risk scores in comparative effectiveness research with emerging therapies

http://www.wikidata.org/entity/Q36266471

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Role of disease risk scores in comparative effectiveness research with emerging therapies

@ast

Role of disease risk scores in comparative effectiveness research with emerging therapies

@en

type

label

Role of disease risk scores in comparative effectiveness research with emerging therapies

@ast

Role of disease risk scores in comparative effectiveness research with emerging therapies

@en

prefLabel

Role of disease risk scores in comparative effectiveness research with emerging therapies

@ast

Role of disease risk scores in comparative effectiveness research with emerging therapies

@en

P1433

Q36266471-8DBE146F-91FB-4FA6-8C56-F93CE1165F0C

P1476

Q36266471-DA13248C-BFBD-4002-BE29-F9048A0EAB43

P2093

Q36266471-6B7B85E9-CC1F-4574-9E56-7CE03C03FF02

Q36266471-831ADC8B-7303-4DB7-B45F-2290C41B68E7

Q36266471-CEAFF313-1848-4A61-B89B-4C7CA6FF28D0

P2860

Q36266471-0CD43F6C-2D8D-498C-893D-5D6D68184876

Q36266471-12DA4BDB-61AF-4125-B0D3-C987A2B592D7

Q36266471-132E1825-279E-4587-8F68-592D188D2291

Q36266471-2236125E-271B-4376-BF88-ADDFF819CE0E

Q36266471-247B99D8-466F-4D27-8CCA-E1DF359737DB

Q36266471-2BD472A1-645C-4A58-A99B-A399DACF0459

Q36266471-2E2F8A5D-33E4-4385-9BF6-C8AA1F1D3563

Q36266471-46A110D4-1E05-4C13-BD78-A4E0CA22EE60

Q36266471-4ADD28D1-4DA5-4E39-BF00-2292EF07DF3A

Q36266471-5A408908-1365-4D9D-AC82-0813E41C2A6C

P304

Q36266471-A780B5BE-0E6F-4F35-A7D4-A8360BF730FC

P31

Q36266471-B84A1619-D048-4E45-ACC3-3EA288D34C63

P356

Q36266471-9D3E7AEB-8687-44D4-BFED-4886E20E7ED4

P478

Q36266471-1E1427AF-51BF-4397-80C5-2EDE17F67BE5

P577

Q36266471-0465D571-9D81-4CD8-AB59-F2ACEB42286F

P5875

Q36266471-F262ADFB-12FF-4517-A79D-1014F517FA92

P698

Q36266471-C4B1F129-F28D-4764-947A-5D70C6FDEC65

P932

Q36266471-D201C855-AFD4-4DF0-97DD-1EFC03E03430

P356

P1433

Pharmacoepidemiology and Drug Safety

P1476

Role of disease risk scores in comparative effectiveness research with emerging therapies

@en

P2093

Joshua J Gagne

http://www.w3.org/2001/XMLSchema#string

Robert J Glynn

http://www.w3.org/2001/XMLSchema#string

Sebastian Schneeweiss

http://www.w3.org/2001/XMLSchema#string

P2860

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

Assessment of coma and impaired consciousness. A practical scale

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

Using the Peters--Belson method to measure health care disparities from complex survey data.

Comorbidity measures for use with administrative data.

High-dimensional propensity score adjustment in studies of treatment effects using health care claims data

Confounder summary scores when comparing the effects of multiple drug exposures

P304

138-147

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PDS.3231

http://www.w3.org/2001/XMLSchema#string

P478

21 Suppl 2

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230626505

http://www.w3.org/2001/XMLSchema#string

P698

22552989

http://www.w3.org/2001/XMLSchema#string

P932

3454457

http://www.w3.org/2001/XMLSchema#string